Tags: barclays capitalRemove, pharmaceuticalsRemove

Strong expansion story allows company to fix conversion price on 25% of the deal in 12 months time; investors compensated by high yield and high bond floor.
By Anette Jönsson | 23 April 2006
1
Magazine
FinanceAsia Magazine
FinanceAsia
December 2011/January 2012